Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

NDAQ:MNMD - Post Discussion

Mind Medicine (MindMed) Inc > Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study
View:
Post by AwareInvestor on Dec 21, 2021 8:23am

Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine this morning indicated that things are not going quite to plan with an IND submission for a Phase 2b trial focused on examining the use of LSD for the treatment of generalized anxiety disorder. The FDA evidently has placed a clinical hold on the study.
Comment by Bubbsy2014 on Dec 25, 2021 7:07am
Paid jerk 
Comment by SouthernTierTom on Dec 29, 2021 9:55pm
You mentioned "paid jerk"? I thought the press release stated that this in fact did happen? Is this incorrect? Do you think it will trend back up towards that 3 BILLION CAD valuation once they "sort it out"? I find your repsonse to "apparent fact" curious and somewhat troublesome...are you OK fella? I feel badly for those that paid $7 CAD on the back of an ~ 3 ...more  
Mind Medicine (MindMed) Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities